https://thehill.com/policy/healthcare/492042-nih-begins-clinical-trial-to-test-hydroxychloroquine-to-treat-covid-19
The National Institutes of Health (NIH) has begun enrolling participants in a clinical trial to test the effectiveness of hydroxychloroquine in treating COVID-19, the agency announced Thursday.
The first participants have enrolled in the trial at Vanderbilt University Medical Center in Nashville, Tenn. The study will be conducted by the NIH’s National Heart, Lung, and Blood Institute.
According to the NIH, the blinded, placebo-controlled randomized clinical trial aims to enroll more than 500 adults who are currently hospitalized with COVID-19, the disease caused by the novel coronavirus, or who are in an emergency department with anticipated hospitalization.
Participants will be randomly assigned to receive 400 mg of hydroxychloroquine twice daily for two doses (day one), then 200 mg twice daily for the subsequent eight doses (days two through five) or a placebo twice daily for five days.
Hydroxychloroquine is used to treat malaria, lupus and rheumatoid conditions such as arthritis. However, its effectiveness at treating COVID-19 has never been proven, despite its embrace by President Trump.